Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA.

Science translational medicine·2026
Same author

Features predicting data exclusion in imaging studies of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Blood-based proteomic signature of amyloidosis: identification of novel regulators of amyloid load.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

No cognitive or psychological impact from returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial.

medRxiv : the preprint server for health sciences·2026
Same author

Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study.

Lancet (London, England)·2026
Same journal

Association of sleep duration with Alzheimer's disease and cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Carling G Robinson1, Alexa Pichet Binette2,3,4, Kanta Horie1,5,6

  • 1Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

性别不会影响陶氏质子发射断层扫描 (PET) 和脑脊液 (CSF) MTBR-tau243生物标志物之间的联系. 这些发现表明,在tau-PET中观察到的性别差异反映了真正的生物学因素,而不是方法学工件.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经成像是一种神经成像.
  • 生物标志物 生物标志物
  • 阿尔茨海默氏症疾病研究研究

背景情况:

  • 之前的研究表明,阳子发射断层扫描 (PET) 结合的性别差异,特别是在患有阿尔茨海默病 (AD) 生物标志物的女性中.
  • 对于-PET中这些性别差异的PET方法论与生物机制的贡献仍然不清楚.
  • 脑脊液 (CSF) 中的微管结合区域tau物种 (MTBR-tau243) 是已确定的AD tau病理生物标志物,但它与tau-PET中的性别差异的关系尚未被探索.

研究的目的:

  • 为了研究CSF MTBR-tau243和tau-PET之间的性别关系.
  • 为了确定性别是否会缓和CSF MTBR-tau243和tau-PET之间的关联.
  • 探索这些关系的个人和没有粉样β (Aβ) 阳性.

主要方法:

  • 来自两个队列 (瑞典BioFINDER-2和骑士ADRC) 的CSF MTBR-tau243和tau-PET数据的横截面分析.
  • Tau-PET成像使用了Flortaucipir (Knight-ADRC) 和RO948 (BioFINDER-2) 标记器.
  • 统计分析的重点是性别和CSFMTBR-tau243之间的相互作用,用于预测时间tau-PET,包括按Aβ状态分层的分析.

主要成果:

  • 在两个队列中,CSF MTBR-tau243和时间-PET之间发现了显著的关联.
  • 没有观察到性别和CSFMTBR-tau243在预测任何队列的时间-PET之间有显著的相互作用.
  • 这些发现在粉样β (Aβ) 阳性亚组中保持一致.

结论:

  • 性别不会调节-PET和CSF MTBR-tau243之间的关系,表明这些是聚合病理学的独特标志物.
  • 在tau-PET中观察到的性别差异可能归因于真正的生物学因素,而不是PET的方法影响.
  • 这项研究澄清了用于阿尔茨海默病研究的tau-PET成像中的性别特异性发现的解释.